206 related articles for article (PubMed ID: 34653248)
1. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease.
Docampo MD; da Silva MB; Lazrak A; Nichols KB; Lieberman SR; Slingerland AE; Armijo GK; Shono Y; Nguyen C; Monette S; Dwomoh E; Lee N; Geary CD; Perobelli SM; Smith M; Markey KA; Vardhana SA; Kousa AI; Zamir E; Greenfield I; Sun JC; Cross JR; Peled JU; Jenq RR; Stein-Thoeringer CK; van den Brink MRM
Blood; 2022 Apr; 139(15):2392-2405. PubMed ID: 34653248
[TBL] [Abstract][Full Text] [Related]
2. GPR Expression in Intestinal Biopsies From SCT Patients Is Upregulated in GvHD and Is Suppressed by Broad-Spectrum Antibiotics.
Ghimire S; Weber D; Hippe K; Meedt E; Hoepting M; Kattner AS; Hiergeist A; Gessner A; Matos C; Ghimire S; Wolff D; Edinger M; Hoffmann P; Poeck H; Herr W; Holler E
Front Immunol; 2021; 12():753287. PubMed ID: 34777363
[TBL] [Abstract][Full Text] [Related]
3. STING negatively regulates allogeneic T-cell responses by constraining antigen-presenting cell function.
Wu Y; Tang CA; Mealer C; Bastian D; Hanief Sofi M; Tian L; Schutt S; Choi HJ; Ticer T; Zhang M; Sui X; Huang L; Mellor AL; Hu CA; Yu XZ
Cell Mol Immunol; 2021 Mar; 18(3):632-643. PubMed ID: 33500563
[TBL] [Abstract][Full Text] [Related]
4. Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation.
Hashimoto D; Chow A; Greter M; Saenger Y; Kwan WH; Leboeuf M; Ginhoux F; Ochando JC; Kunisaki Y; van Rooijen N; Liu C; Teshima T; Heeger PS; Stanley ER; Frenette PS; Merad M
J Exp Med; 2011 May; 208(5):1069-82. PubMed ID: 21536742
[TBL] [Abstract][Full Text] [Related]
5. Dietary Fiber Protects against Diabetic Nephropathy through Short-Chain Fatty Acid-Mediated Activation of G Protein-Coupled Receptors GPR43 and GPR109A.
Li YJ; Chen X; Kwan TK; Loh YW; Singer J; Liu Y; Ma J; Tan J; Macia L; Mackay CR; Chadban SJ; Wu H
J Am Soc Nephrol; 2020 Jun; 31(6):1267-1281. PubMed ID: 32358041
[TBL] [Abstract][Full Text] [Related]
6. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.
Andermann TM; Fouladi F; Tamburini FB; Sahaf B; Tkachenko E; Greene C; Buckley MT; Brooks EF; Hedlin H; Arai S; Mackall CL; Miklos D; Negrin RS; Fodor AA; Rezvani AR; Bhatt AS
Transplant Cell Ther; 2021 Nov; 27(11):932.e1-932.e11. PubMed ID: 34274493
[TBL] [Abstract][Full Text] [Related]
7. Absence of inducible costimulator on alloreactive T cells reduces graft versus host disease and induces Th2 deviation.
Hubbard VM; Eng JM; Ramirez-Montagut T; Tjoe KH; Muriglan SJ; Kochman AA; Terwey TH; Willis LM; Schiro R; Heller G; Murphy GF; Liu C; Alpdogan O; van den Brink MR
Blood; 2005 Nov; 106(9):3285-92. PubMed ID: 15956289
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 regulates CD4
Tsai JJ; Velardi E; Shono Y; Argyropoulos KV; Holland AM; Smith OM; Yim NL; Rao UK; Kreines FM; Lieberman SR; Young LF; Lazrak A; Youssef S; Fu YY; Liu C; Lezcano C; Murphy GF; Na IK; Jenq RR; Hanash AM; Dudakov JA; van den Brink MRM
Blood; 2018 Dec; 132(26):2763-2774. PubMed ID: 30381375
[TBL] [Abstract][Full Text] [Related]
9. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
10. Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.
Gao Y; Shan W; Gu T; Zhang J; Wu Y; Li X; Zeng X; Zhou H; Chen Z; Xiao H
Front Immunol; 2021; 12():785774. PubMed ID: 34987512
[TBL] [Abstract][Full Text] [Related]
11. An essential role for IFN-gamma in regulation of alloreactive CD8 T cells following allogeneic hematopoietic cell transplantation.
Asavaroengchai W; Wang H; Wang S; Wang L; Bronson R; Sykes M; Yang YG
Biol Blood Marrow Transplant; 2007 Jan; 13(1):46-55. PubMed ID: 17222752
[TBL] [Abstract][Full Text] [Related]
12. A single strain of Bacteroides fragilis protects gut integrity and reduces GVHD.
Sofi MH; Wu Y; Ticer T; Schutt S; Bastian D; Choi HJ; Tian L; Mealer C; Liu C; Westwater C; Armeson KE; Alekseyenko AV; Yu XZ
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33554953
[TBL] [Abstract][Full Text] [Related]
13. Microbial metabolite sensor GPR43 controls severity of experimental GVHD.
Fujiwara H; Docampo MD; Riwes M; Peltier D; Toubai T; Henig I; Wu SJ; Kim S; Taylor A; Brabbs S; Liu C; Zajac C; Oravecz-Wilson K; Sun Y; Núñez G; Levine JE; van den Brink MRM; Ferrara JLM; Reddy P
Nat Commun; 2018 Sep; 9(1):3674. PubMed ID: 30201970
[TBL] [Abstract][Full Text] [Related]
14. Mitochondrial Deacetylase SIRT3 Plays an Important Role in Donor T Cell Responses after Experimental Allogeneic Hematopoietic Transplantation.
Toubai T; Tamaki H; Peltier DC; Rossi C; Oravecz-Wilson K; Liu C; Zajac C; Wu J; Sun Y; Fujiwara H; Henig I; Kim S; Lombard DB; Reddy P
J Immunol; 2018 Dec; 201(11):3443-3455. PubMed ID: 30389773
[TBL] [Abstract][Full Text] [Related]
15. Preventive azithromycin treatment reduces noninfectious lung injury and acute graft-versus-host disease in a murine model of allogeneic hematopoietic cell transplantation.
Radhakrishnan SV; Palaniyandi S; Mueller G; Miklos S; Hager M; Spacenko E; Karlsson FJ; Huber E; Kittan NA; Hildebrandt GC
Biol Blood Marrow Transplant; 2015 Jan; 21(1):30-8. PubMed ID: 25445642
[TBL] [Abstract][Full Text] [Related]
16. Antigen-presenting cell-derived complement modulates graft-versus-host disease.
Kwan WH; Hashimoto D; Paz-Artal E; Ostrow K; Greter M; Raedler H; Medof ME; Merad M; Heeger PS
J Clin Invest; 2012 Jun; 122(6):2234-8. PubMed ID: 22585573
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic blockade of JAK1/JAK2 reduces GvHD and preserves the graft-versus-leukemia effect.
Choi J; Cooper ML; Alahmari B; Ritchey J; Collins L; Holt M; DiPersio JF
PLoS One; 2014; 9(10):e109799. PubMed ID: 25289677
[TBL] [Abstract][Full Text] [Related]
18. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
19. Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation.
Lu SX; Kappel LW; Charbonneau-Allard AM; Atallah R; Holland AM; Turbide C; Hubbard VM; Rotolo JA; Smith M; Suh D; King C; Rao UK; Yim N; Bautista JL; Jenq RR; Penack O; Na IK; Liu C; Murphy G; Alpdogan O; Blumberg RS; Macian F; Holmes KV; Beauchemin N; van den Brink MR
PLoS One; 2011; 6(7):e21611. PubMed ID: 21760897
[TBL] [Abstract][Full Text] [Related]
20. Thioredoxin-1 confines T cell alloresponse and pathogenicity in graft-versus-host disease.
Sofi MH; Wu Y; Schutt SD; Dai M; Daenthanasanmak A; Heinrichs Voss J; Nguyen H; Bastian D; Iamsawat S; Selvam SP; Liu C; Maulik N; Ogretmen B; Jin J; Mehrotra S; Yu XZ
J Clin Invest; 2019 May; 129(7):2760-2774. PubMed ID: 31045571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
